Pivekimab, also IBAT®, constitutes a unique recombinant monoclonal antibody engineered to directly target while block interleukin-6, a key molecule involved in multiple inflammatory processes contributing to chronic conditions. The experimental agent has been manufactured using genetic engineering technology processes, allowing for production and

Basiliximab, previously referred to as CHI 621 and possessing the chemical identifier 179045-86-4, represents a antibody agent utilized primarily in preventing acute rejection following organ transplantation . This humanized antibody specifically targets the interleukin-2 (IL-2) sensor , effectively inhibiting IL-2 signaling and subsequently reduci